Referring Patients to Psychedelic Medicine in Europe

This page is an informational summary for GPs and psychiatrists whose patients ask about — or may be candidates for — psychedelic medicine. It is not clinical guidance: indications, contraindications and treatment decisions belong with your judgement and your national guidelines, which this summary defers to throughout. What it offers is the practical layer those guidelines rarely cover — what the receiving centers need from a referral, how the mechanics differ by country, and how to verify that a provider is what it claims to be.

TL;DR The regulated route is esketamine (Spravato), EU-licensed for treatment-resistant depression after ≥2 adequate antidepressant failures in the current moderate-to-severe episode, initiated by a psychiatrist and administered under supervision. A referral stands or falls on the structured medication history; in pre-approval systems (Switzerland, Belgium, Finland) it is literally the reviewed document. Off-label ketamine is lawful but sits outside most national guidelines' recommendations. Psilocybin and MDMA remain investigational, with three narrow national exceptions. Trials are a real referral option. This directory verifies providers against national registries and shows the date of the last check.

When to consider a referral

The anchor definition is the EU label: esketamine nasal spray is authorised, in combination with an SSRI or SNRI, for adults with treatment-resistant major depressive disorder — no response to at least two different antidepressants at adequate dose and duration in the current moderate-to-severe episode (EMA EPAR). The evidence behind that indication includes short-term benefit (TRANSFORM-2), relapse prevention (SUSTAIN-1) and superiority over extended-release quetiapine on remission (ESCAPE-TRD) — summarised with citations in our esketamine evidence review. Germany's G-BA moved from "added benefit not proven" (2021) to "considerable added benefit" (2023) on the strength of ESCAPE-TRD (G-BA) — useful context when discussing the option with colleagues or payers.

Note that several systems gate reimbursement more strictly than the label: the Netherlands and Switzerland require a failed augmentation attempt on top of two antidepressants, Spain and Finland count three failed strategies, and age limits (under 65 in France and Czechia, 18–74/75 elsewhere) and severity thresholds (CGI-S ≥5 in Switzerland, MADRS ≥31 in Finland) apply in places. "Adequate trial" is assessed on dose and duration, not intention — which is why documentation decides these cases. Where your patient does not meet criteria, exceptional individual-funding routes exist in several systems (documented practice in Czechia; statutory mechanisms in Germany and Switzerland) — see the reimbursement map.

Off-label racemic ketamine is lawful when prescribed by a licensed physician, but national depression guidelines are generally conservative about it — Germany's places it in inpatient psychiatric settings — and coverage is rare (Norway's public funding of generic IV ketamine, from August 2025, is the exception). The evidence base and its limits are summarised in our ketamine evidence review.

What the receiving center needs from you

Across every esketamine pathway, the referral that gets accepted quickly contains the same core file. In pre-approval systems — Switzerland, Belgium, Finland, and Czechia beyond standard criteria — this file is what the insurer's advising physician reads before the first dose is scheduled, so completeness here is the difference between weeks and months:

A structured medication history for the current episode: each antidepressant with substance, maximum dose reached, duration at that dose, measured outcome, adverse effects, and reason for discontinuation — plus any augmentation strategies (lithium, atypical antipsychotics) in the same format;
Psychotherapy history: modality, approximate duration, outcome (a criterion in Finland, relevant context everywhere);
Diagnosis and episode course, with severity ratings where your system uses them (MADRS, CGI-S) and dates;
Psychiatric screening findings, in particular personal or family history of psychosis and bipolar disorder;
Cardiovascular status and blood pressure, given the label's contraindications (aneurysmal vascular disease, intracerebral haemorrhage history, recent cardiovascular events);
Complete current medication and relevant somatic history;
Substance-use history and a current risk assessment.

Prescribing and initiation are psychiatrist-led in every country; the GP's role is referral and the history above. Administration is always supervised on site with a post-dose observation period, and patients must be advised not to drive for the rest of the treatment day.

Country mechanics in one line each

Country	The route in one line	Details
Germany	GKV-covered; office-based practices since 10/2023 with own billing code — budget objections do not hold	guide
Netherlands	Basic package; referral to an ENC-NL specialized center; 2 antidepressants + 1 augmentation required	guide
Poland	NFZ program B.147; referral to a contracted center, live waiting times on the national portal; 34-week cap	guide
Switzerland	52 BAG-designated centers; center files the Kostengutsprache before first dose; 10-month cap	guide
UK	England/Wales: no NHS route (TA854), private CQC clinics only; Scotland: SMC-accepted NHS route	guide
France	Hospital psychiatry only, under 65, 2 failed antidepressants of 2 classes; no private market	guide
Spain	Hospital-financed, 3 failed strategies; expect regional variation between autonomous communities	guide
Czechia	Reimbursed since 02/2025, under 65, via equipped psychiatric facilities; exceptional approval possible	guide

For Belgium, Italy, Ireland, Finland, Portugal, Denmark, Sweden, Norway and Austria, the criteria and deciding bodies are tabulated in the reimbursement map.

Trials as a referral option

Where reimbursement is closed or criteria exclude your patient, a clinical trial is often the strongest lawful option — free by definition, ethics-supervised, and the only current route to psilocybin or MDMA in most of Europe. Active European programs in 2026 include Compass Pathways' psilocybin Phase 3 work, atai/Beckley's BPL-003 program (sites in Germany, Poland, Spain and the UK), GH Research (around 20 sites in seven countries) and MindMed. Search ClinicalTrials.gov and the EU's CTIS portal, and point patients to our trials guide for an honest account of phases, placebo arms and screen-fail rates; per-country trial-site listings sit under each country page (for example, trial sites in Czechia). Screening is strict, enrolment is never guaranteed, and a referral letter with the medication history above shortens the site's own work considerably.

For psilocybin and MDMA outside trials, the honest line for patients is short: three narrow national exceptions exist (Switzerland's limited medical use program, Germany's two-site psilocybin compassionate use program, Czechia's not-yet-delivering framework), and any commercial offer elsewhere is operating outside the law — the Europe-wide comparison has the details.

What this directory verifies — and how to use it

Every provider listing here is matched against the registry that actually governs it: the NFZ B.147 center list in Poland, the BAG designated-center list in Switzerland, ENC-NL criteria in the Netherlands, the CQC register in the UK, Ärztekammer and institutional registers in Germany, and national healthcare-entity registers elsewhere. Each record shows which registry it was checked against, the source link, and the date it was last verified; registry-verified records are re-checked at least every 90 days, and records that have not yet been matched are labelled as unverified rather than hidden. The full workflow is on the methodology page.

In practice: before referring to an unfamiliar center, check its listing status and last-verified date here, then confirm current intake directly with the center — designated-center lists change when payers update them, and waiting times move faster than any directory.

Professional resources and further reading

Blossom — continuously updated country-level access and reimbursement reporting;
Psychedelic Alpha — legal and regulatory tracking worldwide;
Magnetar Access × Blossom reimbursement report — the sector reference on European payer pathways;
EUDA FAQ on therapeutic use of psychedelics — the EU agency's plain-language evidence summary;
Our substance evidence reviews with primary citations: esketamine, ketamine, psilocybin, MDMA.

Your national depression guideline remains the reference for treatment sequencing; nothing here replaces it.

Frequently asked questions

Can a GP refer directly, or does the patient need a psychiatrist first?

Esketamine initiation is psychiatrist-led in every European system, so the GP's referral goes to psychiatry or directly to a treating center, accompanied by the medication history. In designated-center systems (Switzerland, the Netherlands, Poland) the referral ultimately lands at a listed center; in Germany, office-based psychiatrists can now prescribe and administer themselves.

What single thing speeds up acceptance most?

The structured medication history, with doses, durations and outcomes for the current episode. Centers report that assembling proof of two adequate failed trials is routinely the slowest step, and in pre-approval systems the payer's physician decides on that document alone. Sending it complete with the referral can save weeks.

Is prescribing off-label IV ketamine defensible in outpatient settings?

It is lawful for a licensed physician, and a private market operates in several countries — but most national guidelines take a conservative position (Germany's places it in inpatient care), coverage is generally absent, and repeated-use risks (bladder toxicity, dependence) require structured follow-up. Document the rationale, exhausted alternatives and consent carefully, and defer to your national guideline's position; our ketamine evidence review summarises the data honestly.

What should I tell patients asking about psilocybin or MDMA therapy?

That both remain investigational in the EU: psilocybin's Phase 3 program met its primary endpoints, MDMA's approval was declined by the FDA in 2024 pending further data, and neither has an EU marketing authorisation. Lawful access today means a clinical trial or one of three narrow national programs — and any commercial offer outside those is illegal, with none of the screening that makes supervised use manageable.

For clinics and practitioners

If you operate a clinic, hospital program or trial site listed here — or one that should be — you can claim your listing, correct its details, or submit it for verification via the contact page. Listing is free, inclusion is determined solely by registry verification, and verified records display their registry source and last-checked date. The verification workflow is run by the PsyStandard team using the registry-matching process described on the methodology page.

Sources

This page is an informational summary for healthcare professionals, not clinical guidance, medical advice or a recommendation of any treatment. Indications, criteria and coverage change; always defer to your national guidelines, the current SmPC and the responsible payer. Patients in crisis should be directed to emergency services immediately.

This guide awaits review by a licensed medical professional.

For Clinicians: Referring a Patient to Psychedelic Medicine in Europe